Adam O’Dell’s Imperium Review: Is Green Zone Fortunes Worth It?

Adam O’Dell has been pitching some version of “Imperium” since February of 2021. The Green Zone Fortunes presentation is back, this time with a fresh coat of paint and a 2027 calendar on the wall, and the framing is built around a single question: is “Imperium” the “No. 1 investment for 2027?” The argument underneath is a technology tipping point. A new silicon “biochip” has, in O’Dell’s telling, made DNA “fast enough, cheap enough, and scalable enough to surge into the mainstream,” and the company that makes that chip is, he says, the next IBM, Intel, and Nvidia rolled into one.

We read the full pitch, checked the paper trail, and dug into the offer’s fine print. Here is what we found.

The Presenter

Adam O’Dell is the chief investment strategist at Money & Markets, the publishing house behind Green Zone Fortunes, and he also runs two related services, Cycle 9 Alert and 10X Profits. His method leans heavily on a quantitative, systems-driven screen: the Green Zone Power Ratings, a proprietary system that scores stocks and sorts them into a “green zone” of buys and a “red zone” of sells using momentum, value, and volatility inputs. That discipline is a real framework, not a gimmick, and it gives his recommendations a consistency that a lot of newsletter pitches lack.

His strongest recent call is well documented. O’Dell began teasing Palantir in the spring of 2024, when the stock was still trading in the $20s, and it went on to be the best-performing stock in the S&P 500 for 2024. That is a checkable, dated win on a large, liquid name, and the presentation leans on it correctly as evidence that he can spot a “zero to one” company before the crowd. He frames the Imperium thesis through the same lens, quoting Peter Thiel’s idea that the best investments do not fit any pre-existing category at the time you buy them.

The track record on Imperium specifically is more mixed, and precision matters here. O’Dell first teased Twist Bioscience as his Imperium play in February 2021, when the stock was in the $120s. He kept promoting it through the biotech collapse of 2022 and 2023, as the shares slid toward the $20s, then swapped Twist out for PacBio in the spring of 2024, a call that never worked out, and has now returned to Twist for this 2027 edition. None of that makes him wrong this time. It does mean the Imperium theme is a recurring, refreshable marketing franchise, and the specific picks underneath it have changed over the years. That is worth keeping in mind when the pitch leans on the size of the opportunity rather than the consistency of the calls.

The Big Idea

Imperium is O’Dell’s coined word for the synthetic-biology megatrend: the idea that DNA, once it can be read, written, and manufactured like computer code, turns every industry that sells an animal, a plant, a fiber, or a molecule into a software problem. His phrasing is memorable for a reason. “Once you can read, design, and write the code of living things,” the pitch runs, “every industry that sells an animal, a plant, a fiber, or a molecule is suddenly just a software problem.”

The presentation builds a familiar three-layer stack, borrowed straight from the personal-computer era, and maps each layer to a company.

Twist Bioscience (TWST) is the “silicon layer,” the Intel of the DNA revolution. Twist makes synthetic DNA, and its patented NanoWell technology synthesizes DNA on silicon chips rather than in test tubes. O’Dell’s claim is that this “processes DNA at 10,000 times the speed of the previous technology.” The partner list is impressive on paper: Amazon, Microsoft, Johns Hopkins, Illumina, and DARPA all show up as customers or collaborators.

Ginkgo Bioworks (DNA) is the “software layer,” the Microsoft. O’Dell casts Ginkgo as the operating system that sits between the silicon layer and the applications, and he leans on a quote from Twist’s own chief executive, who once said “We’re Intel, they’re Microsoft.” The pitch is that a standardized platform lets apps build on top, the same way Windows sat on top of Intel chips.

Absci (ABSI) is the “apps layer,” the number-one DNA app set to cure balding. Absci’s lead program, ABS-201, targets male-pattern baldness and endometriosis, and Eli Lilly recently took a stake. The promo notes that male-pattern baldness affects roughly 1.5 billion people, a figure O’Dell uses to argue the “software problem” of hair loss is one of the biggest and most profitable a DNA company could solve.

The urgency engine is what O’Dell calls a “leap moment,” the point where a specific breakthrough pushes a technology into the mainstream. His version of that breakthrough is the biochip, and the framing is that you are being offered a seat before the crowd arrives.

The Key Claims

The numbers in this presentation are characteristically large, so it is worth laying them out and taking each one on its own terms.

The $65 trillion claim. O’Dell cites McKinsey in arguing that Imperium “will disrupt 60% of the physical inputs in the global economy,” remaking “entire industries worth $65 trillion from the ground up.” That is a big, directional claim about a real, well-funded field. It is also an upper-bound framing meant to make the opportunity feel total rather than specific.

The “next Nvidia” claim. His “#1 Imperium company” is pitched as the next “IBM, Intel, Nvidia” in sequence, with “a real path to becoming the biggest company in the world” while sitting “over 600 times smaller than Nvidia right now.” The implication is a 600-times runway. The honest read is different: a life-sciences tools business is not a chip monopoly, and being smaller than Nvidia is not, by itself, the opportunity.

The “10,000 times faster” claim. This one attaches to a real technology, Twist’s NanoWell silicon synthesis, but the 10,000-times figure is a marketing number we cannot independently verify. The underlying trend, that DNA synthesis keeps getting cheaper and faster, is broadly true.

The four-month “six times” claim. O’Dell says a “DNA index” returned “more than six times the money” of the semiconductor index over the last four months. That is a four-month window, far too short to mean anything about a decade-long revolution.

The 55,000% claim. O’Dell says DNA data storage will grow “almost 55,000% over the next decade,” tied to a Twist spin-off in which Twist kept a 25% stake plus royalty agreements. A 55,000% growth projection is an extrapolation so aggressive it functions as a headline rather than a forecast, and it attaches to a market, DNA data storage, that is still in the research stage.

There is a real signal buried in the noise. Amazon genuinely set up a program to design DNA applications and selected Twist as its silicon layer and Ginkgo as its software layer. That is a modest, verifiable validation of the two companies’ relationships with serious buyers, even if the promo folds it into a “Wintel of the DNA revolution” narrative that runs ahead of it.

The Free Tickers

No stock is given away free on camera in this one. O’Dell teases three companies across three special reports, and the whole pitch is built to get you to subscribe so the reports can name them. Stock Gumshoe’s Thinkolator resolved all three, and our own teardown confirms the two new ones. Here they are.

Twist Bioscience (TWST), teased around $112, now near $116. This is the “#1 Imperium stock,” the silicon layer, and the financial story underneath it is real and steady. Twist has posted 15 consecutive quarters of revenue growth at roughly 20% a year, carries a market cap around $7.6 billion, and now sits near break-even on an adjusted cash-flow basis. Analysts model about $1.50 in adjusted earnings per share by fiscal 2028. The stock has also become an AI story: Twist uses AI to speed up DNA synthesis and protein discovery, and a high-profile Eli Lilly drug-discovery deal plus an Anthropic collaboration sent shares soaring late in the summer. The catch is valuation. BWS Financial initiated coverage in September with a Sell rating and a $45 target, arguing Twist trades at a meaningful premium in a competitive tools market, and Hunterbrook published a cautionary note whose headline question was blunt: “Last time, TWST fell 95%. Could it happen again?”

Ginkgo Bioworks (DNA), teased around $8.32, now near $8.44. This is the “Microsoft of the DNA revolution,” founded by five MIT PhDs and, at its 2021 SPAC-era peak, briefly worth around $20 billion. It is now worth roughly $539 million, one of the more dramatic drawdowns of that boom. The business has changed course: instead of selling custom molecules, the original “foundry” plan, Ginkgo now sells autonomous “DNA factories,” robotic lab equipment for AI and pharma companies. Its first autonomous-lab sale went to Novo Nordisk, and it has new government wins with ARPA-H and the NSF. That is a genuine pivot with real traction, but it is a speculative turnaround bet against a crowded field that includes Thermo Fisher and roughly a dozen autonomous-lab startups, not a compounding monopoly.

The third pick, Absci (ABSI), teased around $7.58, is the “number-one DNA app” aimed at male-pattern baldness. We have already covered Absci in depth in our Absci AI drug discovery teardown, so we will not re-litigate it here, but note that its proof-of-concept data is due in December, with full results in early 2027.

What You Get

The subscription runs $297 a year with a 30-day refund period, which sits toward the cheaper end of the newsletter spectrum. For that you get the Green Zone Fortunes service itself, O’Dell’s model portfolio and ratings, and the three special reports that carry the teased names:

  1. “Beyond NVIDIA: The World’s Next #1 Stock”, the Twist Bioscience report and the centerpiece of the pitch.
  2. “The Microsoft of the $65 Trillion DNA Revolution”, the Ginkgo Bioworks report.
  3. “The #1 DNA ‘App’ Set to Cure Balding”, the Absci report.

The source material does not state a renewal price, so treat the $297 as the first-year figure and confirm the renewal terms on the order page before you commit. The 30-day refund window is a standard, reasonable protection, and it effectively makes the reports refundable if the pitch does not hold up under your own reading.

Our Take

Buy the theme, not the certainty. The synthetic-biology trend is real and getting more interesting. Illumina, Thermo Fisher, and Danaher compete at the equipment layer, and DARPA, ARPA-H, the NSF, Amazon, Eli Lilly, and Anthropic have all put real money into DNA synthesis and DNA-driven drug discovery. O’Dell’s underlying claim, that DNA technology is getting faster and cheaper and that this matters, is broadly correct.

Twist is a legitimate, growing company with genuine partners and a genuine, if pricey, story. Fifteen consecutive quarters of roughly 20% revenue growth and a near-break-even cash position are facts, not hype. But the promo’s framing, that TWST is the next Nvidia with a 600-times runway, runs well ahead of the evidence. The Sell rating and $45 target from BWS, and Hunterbrook’s reminder of the last 95% drawdown, both point at a rich valuation rather than a hidden bargain. Treat Twist as a watchlist idea you buy at a price you can defend, not at any price the pitch implies.

Ginkgo is a different animal entirely. The “Microsoft of the DNA revolution” line rests on a 2015 quote from a company whose business model has changed completely since, and whose actual record is a $20 billion-to-$539 million collapse with missed revenue projections and heavy dilution. The autonomous-lab pivot is genuinely interesting, and a Novo Nordisk sale plus ARPA-H and NSF wins are concrete, but this is a speculative turnaround bet against well-funded competition, not a core holding.

The headline numbers, the “600 times smaller than Nvidia” runway, the “55,000%” data-storage growth, and the four-month “six times” return, are the parts of the pitch to discount the hardest. They are engineered to feel like the opportunity is total rather than specific, and they do not survive a close read.

For most readers, the practical takeaway is this: the trend is worth owning, the certainty is not, and the individual names carry biotech-level volatility. O’Dell is a real analyst with a real, verifiable Palantir win and a disciplined system. He is also selling a refreshed version of a theme he has run since 2021, with picks that have changed under it. That is worth knowing before you subscribe.

Where to Learn More

NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.